Critical Review: Vera Therapeutics (NASDAQ:VERA) versus Inventiva (NASDAQ:IVA)

Vera Therapeutics (NASDAQ:VERA) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Insider and Institutional Ownership

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Vera Therapeutics and Inventiva, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1	2	9	0	2.67
Inventiva	1	0	7	2	3.00

Vera Therapeutics currently has a consensus target price of $77.18, suggesting a potential upside of 77.43%. Inventiva has a consensus target price of $16.22, suggesting a potential upside of 175.89%. Given Inventiva’s stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Vera Therapeutics.

Earnings & Valuation

This table compares Vera Therapeutics and Inventiva”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$152.15 million	($3.99)	-10.90
Inventiva	$13.61 million	63.05	-$199.34 million	N/A	N/A

Vera Therapeutics has higher earnings, but lower revenue than Inventiva.

Profitability

This table compares Vera Therapeutics and Inventiva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-50.92%	-42.67%
Inventiva	N/A	N/A	N/A

Volatility & Risk

Vera Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Inventiva beats Vera Therapeutics on 7 of the 11 factors compared between the two stocks.

About Vera Therapeutics

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.